Pharmako receives TGA approval for its manufacturing facility

March 5, 2021
Alissa Marrapodi

Pharmako Biotechnologies, the sister company of Gencor in the U.S., received approval from the Therapeutic Goods Administration (TGA), Department of Health and Aging for the Government of Australia, for its manufacturing facility.

Pharmako Biotechnologies (N.S.W., Australia), the sister company of Gencor in the U.S., received approval from the Therapeutic Goods Administration (TGA), Department of Health and Aging for the Government of Australia, for its manufacturing facility. Pharmako is now a licensed manufacturer for the production of active pharmaceutical ingredients (APIs) with advanced dispersion and solubility technologies, including its pre-mixes, capsules, liquids and powders. 

“We are pleased to have received TGA approval for our facility in Australia,” said Eric Meppem, co-founder and commercial director, Pharmako, in a press release. “Given the stringent requirements of the TGA for the manufacturing of APIs, we feel even more confident in our ability to exceed the quality assurance demands of our customers.” 

“The granting of this license reflects the level of dedication and effort from our Quality Team and the entire Pharmako staff,” continued Meppem. “Pharmako proudly exports materials all around the world, and this full license justifies the trust international clients place in the quality of Australian manufacturing.”